Skip to main content

Any occurrence of stroke is one too many.

The reality of stroke

Life-changing. Far-reaching. Expensive. The impacts of post-Transcatheter Aortic Valve Replacement (TAVR) disabling stroke create a ripple effect of consequences.

profile images of stroke patients

Over time, TAVR complications have declined—except for stroke. 

Despite clinical and technological advancements, the rate of reported perioperative stroke is holding steady at 2-4%.1-6

Devastating patient impact

It is impossible to predict which procedures will dislodge embolic debris, and when it will cause disabling stroke.

Stroke is the leading cause of permanent disability – the long-term effects are serious including impaired ability to communicate and restricted physical abilities. It is also a primary risk factor for future clinical stroke, dementia, cognitive decline, and mortality.

#1 cause of permanent disability

Stroke is the leading cause of long-term disability.⁷

#1 patient fear

Stroke is the top concern of TAVR patients, even more than death.⁸

78% of patients

say maintaining independence is ther top goal post-TAVR.⁹

Disabling stroke: physical effects¹⁰

Impaired speech icon

Impaired speech

Memory loss icon

Memory loss

Vision problems icon

Vision problems

Limb paralysis or weakness icon

Limb paralysis or weakness

The cost of stroke

For hospitals, the financial implications of all stroke include extended inpatient care, rehabilitation, and follow-up care. 

33% higher

Total average hospitalization cost¹¹

6 days

Longer average length of stay¹¹

31% higher

Average hospital readmission rate¹¹

The high cost of disabling stroke

Disabling stroke substantially increases both short- and long-term treatment costs.

For patients, the need for long-term care, skilled nursing, and rehabilitation facilities drives up costs by as much as 121%. 

ACUTE: $59,010

Estimated cost: Acute Severe Ischemic Stroke¹²

1-Year: $132,590

One-year post-stroke cumulative cost¹²

Long-Term: $206,170

Two-year post-stroke cumulative cost¹²


SENTINEL™ leads the way in clinical evidence for cerebral embolic protection

Sign up

Get exclusive product updates, training and educational opportunities, and more.

Talk to a rep

Fill out a quick form and one of our sales representatives will be in touch.


1. Manoharan G, et al., J Am Coll Cardiol Intv 2015; 8:1359-67.

2. Wendler O, et al., Circulation 2017; 135: 1123–1132.

3. Seeger J, et al., Eur Heart J. 2018 Dec 24. doi: 10.1093/eurheartj/ehy847.

4. Haussig S et al., JAMA 2016; 316:592–601.

5. Kapadia S, Kodali S, Makkar R, et al., Protection against cerebral embolism during transcatheter aortic valve replacement. JACC. 2017; 69(4): 367–377.

6. Kapadia, et al. New England Journal of Medicine, 387(14), 1253–1263. Sep 2022.

7. Tsao CW, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association external icon. Circulation. 2022;145(8):e153–e639.

8 Audience survey, Hawkey M, presented at ACC 2016

9. Coylewright M, Palmer R, O’Neil E, et al., Patient-defined goals for the treatment of severe aortic stenosis: A qualitative analysis. Health Expect. Oct 2016:19(5): 1-36-1043.

10. American Stoke Association: The Effects of Stroke. Available at:

11. Alqahtani F, et al. Clinical and economic burden of acute ischemic stroke following transcatheter aortic valve replacement. Structural Heart. 2018;3(1):72:73.

12. Reddy et al. Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin Versus NOACs Versus LAA Closure. JACC Vol. 66, No. 24, December 22, 2015

All photographs taken by Boston Scientific. Illustrations for informational purposes only – not indicative of actual size or clinical outcome.

All trademarks are property of their respective owners.